Table 1 Patient’s characteristics
Chemo-naïve (n = 58) | Post-chemo (n = 52) | |
|---|---|---|
Age, years | ||
Median | 77 | 66 |
Range | 56–92 | 39–85 |
≥75 (%) | 37 (63.8) | 11 (21.2) |
ECOG performance status, No. (%) | ||
0–1 | 36 (62.1) | 45 (86.5) |
2 | 18 (31.0) | 7 (13.5) |
3 | 4 (6.9) | 0 |
4 | 0 | 0 |
Gleason score at time of initial diagnosis (%) | ||
<8 | 24 (41.4) | 19 (36.5) |
≥8 | 16 (27.6) | 29 (55.8) |
Unknown | 18 (31.0) | 4 (7.7) |
Median PSA (range), ug/l | 212 (6.22–3095) | 191 (4.2–4694) |
Median PSA doubling time (range), months | 2.1 (0.5–9.0) | 2.3 (0.7–13.4) |
Symptomatic at presentationa, No. (%) | 19 (32.8) | 16 (30.8) |
Baseline Hb (g/dl), median (range) | 12 (5.2–15.5) | 11.7 (5.7–14.9) |
Baseline ALP (IU/l), median (range) | 116.5 (40–2960) | 119 (45–1857) |
Disease location, No. (%) | ||
Bone only | 35 (60.3) | 28 (53.8) |
Bone | 55 (94.8) | 50 (96.2) |
Lymph node | 22 (37.9) | 20 (38.5) |
Lung | 2 (3.4)b | 3 (5.8) |
Liver | 3 (5.2)b | 5 (9.6) |
Co-morbidities, No (%) | ||
Diabetes Mellitus | 16 (27.6) | 8 (15.4) |
Hypertension | 32 (55.2) | 20 (38.5) |
Hyperlipidemia | 0 | 4 (7.7) |
Atrial fibrillation | 1 (1.7) | 1 (1.9) |
Congestive heart failure | 1 (1.7) | 0 |
No. of previous cytotoxic regimen (%) | ||
1 | 0 | 44 (84.6) |
2 | 0 | 7 (13.5) |
3 | 0 | 1 (1.9) |
Disease progression prior AA (%) | ||
Biochemical progression only | 42 (72.4) | 35 (67.3) |
Clinical or radiographic progression | 16 (27.6) | 17 (32.7) |